 placebo-control trial zidovudin treatment human immunodefici viru infect asymptomat patient hemophilia nhf-actg studi group ninety-thre asymptomat patient hereditari coagul disord human immunodefici viru hiv infect control trial zidovudin zdv placebo averag month studi pretreat characterist placebo drug-treat group distribut type disord transaminas abnorm use variou hemostat agent time analysi patient treatment endpoint diseas progress treatment twenty-f patient toxic effect granulocytopenia anemia patient subject symptom asthenia malais nausea consist known consequ treatment mg zdv time trend diagnos acquir immunodefici syndrom aid earli aids-rel complex arc singl arc symptom death placebo recipi zdv patient hemophilia rapid diseas progress efficaci analysi patient year treatment subgroup similar trend regard advanc problem infect patient patient aid placebo group none zdv group patient pretreat distribut count placebo zdv group similar patient year cell patient year benefici zdv effect trend count increas zdv group week four-cel increas placebo group signific differ weight gain zdv patient year pound placebo patient year pound week find asymptomat hemophil patient year use effect zdv similar observ studi use asymptomat nonhemophil patient